Senzime AB (publ)
SEZI
Classement en actions
#25303
Senzime AB (publ) is a medical technology firm specializing in the creation and... Senzime AB (publ) is a medical technology firm specializing in the creation and distribution of advanced patient monitoring solutions. These systems are designed to oversee patients undergoing anesthesia across various global markets, including Europe, Oceania, Asia, Canada, and the United States. Among its primary offerings is the TetraGraph, a sophisticated monitor designed to assess and display muscle function in surgical patients administered neuromuscular blocking agents, by stimulating, measuring, and analyzing responses. This system is complemented by the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. For data management, TetraConnect serves as a portal, allowing clinicians to conveniently access, view, and export TetraGraph data records in PDF or Excel formats. Furthermore, TetraGraph Device Connectivity facilitates the transfer of data from the TetraGraph Monitor to other patient monitoring systems, while the TetraGraph Philips Interface specifically enables the transmission of critical neuromuscular monitoring parameters—such as TOFC, TOFR, PTC, and TOF bars—to Philips patient monitors, with readings visible on the Philips Intellivue Monitor. Senzime is also actively developing the CliniSenz Analyzer, intended for continuous postoperative patient monitoring within hospital settings. Another innovation in its pipeline is the Onzurf Probe, a sterile, CE-marked single-use device leveraging micro-dialysis technology for continuous sampling from gastrointestinal organs, including the esophagus, stomach, and liver. The company maintains a strategic licensing and connectivity partnership with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to integrate seamlessly with Masimo's Root monitoring system and their digital hubs, thereby enabling interaction with hospital clinical information systems and electronic health records. Established in 1999, Senzime AB (publ) operates from its headquarters in Uppsala, Sweden.
Prix de l'action
$0.30771569
Capitalisation boursière
$48.38M
Changement (1 jour)
-3.16%
Changement (1 an)
-52.66%
Pays
SE
Échange Senzime AB (publ) (SEZI)
Catégorie
Healthcare
Historique du rendement du dividende pour Senzime AB (publ) (SEZI)
Le rendement du dividende (TTM) de Senzime AB (publ) (symbole boursier : SEZI) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Senzime AB (publ) (SEZI) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
| Année | Rendement du dividende | Changez |
|---|---|---|
| Pas assez de données pour les dates fournies. | ||
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
| Entreprise | Rendement du dividende | Pays |
|---|---|---|
| 2.45% |
US
|
|
| 3.69% |
IE
|
|
| 1.25% |
US
|
|
| 0.00% |
US
|
|
| 0.00% |
DE
|
